Reshape Lifesciences (OTCMKTS:RSLS) is set to announce its earnings results after the market closes on Thursday, November 14th.
Reshape Lifesciences (OTCMKTS:RSLS) last announced its quarterly earnings data on Wednesday, August 14th. The medical device company reported ($0.84) earnings per share (EPS) for the quarter. Reshape Lifesciences had a negative net margin of 689.90% and a negative return on equity of 86.52%. The company had revenue of $4.45 million for the quarter.
Shares of OTCMKTS RSLS traded down $0.01 during trading on Friday, hitting $0.05. 145,798 shares of the company traded hands, compared to its average volume of 148,511. Reshape Lifesciences has a 1 year low of $0.04 and a 1 year high of $7.32. The company has a 50-day moving average price of $0.14 and a 200-day moving average price of $0.11. The company has a quick ratio of 0.93, a current ratio of 1.04 and a debt-to-equity ratio of 0.05.
ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.
Recommended Story: Street Name
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.